3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
14
Phase 1
8
Phase NA
2
Phase 3
2
Phase 4
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Breast Neoplasms
9
Prostatic Neoplasms
7
Neoplasms
5
Multiple Myeloma
5
Leukemia, Myeloid, Acute
3
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Leiomyoma
2
Colorectal Neoplasms
2
Vomiting
1
Venous Thromboembolism
1
Tumor Lysis Syndrome
1
Tuberous Sclerosis
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Thoracic Neoplasms
1
Thalassemia
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Substitutes
1
Skin Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Primary Myelofibrosis
1
Post-operative Seroma Formation
1
Polycythemia Vera
1
Interventions
nilotinib
1
bosutinib
1
asciminib
1
Imatinib Mesylate
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
30 days
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled